Desloratadine vs Bilastine: Approved Strengths
Desloratadine is approved at 5 mg once daily, while bilastine is approved at 20 mg once daily for adults and adolescents 12 years and older. 1
FDA-Approved Dosing
Desloratadine
- Standard strength: 5 mg tablet, taken once daily 1
- May be taken without regard to meals 1
- For patients with hepatic or renal impairment: 5 mg every other day 1
Bilastine
- Standard strength: 20 mg once daily 2
- This is the approved dose in 28 European countries for allergic rhinoconjunctivitis and urticaria in adults and children over 12 years 3, 4
Clinical Context: Comparative Efficacy at Standard Doses
While the question asks about strength (dosing), understanding comparative efficacy at these approved doses is clinically relevant:
At their respective standard doses (bilastine 20 mg vs desloratadine 5 mg), bilastine demonstrates superior antihistaminic activity. In head-to-head comparison, bilastine 20 mg showed significantly greater inhibition of histamine-induced wheal and flare responses compared to desloratadine 5 mg throughout a 24-hour period (83% vs 38% maximum wheal inhibition at 6 hours, p < 0.001) 5. However, for overall symptom control in seasonal allergic rhinitis, both medications showed comparable clinical efficacy 2.
Important Dosing Considerations
- Desloratadine can be up-dosed: In non-responsive chronic spontaneous urticaria patients, desloratadine can be increased to 10 mg daily (double the standard dose) with demonstrated safety and efficacy 6, 7
- Bilastine can be up-dosed: Guidelines support up-dosing bilastine to four times the conventional dose (80 mg daily) in refractory cases with excellent safety profile 7
- Both medications are non-sedating at recommended doses 8